Human genetics testing firm 23andMe announced Tuesday it will voluntarily delist from the Nasdaq and deregister with the U.S.

Me's sale to Regeneron transfers genetic data for drug development, raising privacy issues and concerns over consumer control ...

Regeneron Pharmaceuticals has announced that it will be acquiring human genetics and biotechnology company 23andMe for $256m.

You've still got about a month and a half to claim your share of 23andMe's $30 million settlement. Genetic testing company ...

A crucial step in handling the sale of genetic data from over 15 million 23andMe customers now rests largely in the hands of ...

Regeneron will acquire 23andMe’s core assets for $256 million, ensuring customer data privacy and continuing the mission of ...

On 23 March 2025, the direct-to-consumer genetic testing company 23andMe filed a voluntary Chapter 11 petition in a US bankruptcy court.1 The objective of this bankruptcy is to sell the company ...

Genetic testing company 23andMe had 15 million consumers who turned to them to learn more about their ancestry and understand their disposition to diseases.

There is nothing more inherently unique and personal to an individual than his or her DNA. Unlike many other types of personal information, a ...

Republican Sen. John Cornyn and Democratic Sen. Amy Klobuchar are rolling out a measure to protect sensitive genetic data after 23andMe fled for bankruptcy.